Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc. (XRTX) news covers a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and related disorders driven by aberrant purine metabolism and elevated uric acid. Company updates emphasize programs that target xanthine oxidase, a key enzyme in uric acid production, and explore how genetic and molecular insights can inform treatment strategies.
Readers of this page can follow announcements on XORTX’s lead XRx-026 gout program and its proprietary oxypurinol formulation XORLO™, including regulatory interactions, Investigational New Drug (IND) preparation, clinical trial plans, and progress toward potential New Drug Application (NDA) submissions. News also highlights development of XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney and organ injury associated with respiratory virus infections, and XRx-225 for Type 2 diabetic nephropathy.
In addition to clinical and scientific milestones, XRTX news items report on financing activities such as registered direct offerings, at-the-market issuances, and private placements, as well as Nasdaq listing updates, including minimum bid price deficiency notices and compliance timelines. Corporate developments, including board changes, strategic planning, and the planned acquisition of the VB4-P5 renal anti-fibrotic program from Vectus Biosystems Limited, are also covered.
This news feed brings together scientific findings on xanthine oxidase and uric acid, regulatory and clinical progress in gout and kidney disease programs, and capital markets disclosures. Investors and observers can use it to monitor how XORTX’s research, pipeline evolution, and financing decisions shape the company’s efforts in gout and kidney-related therapeutics.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. Dr. Allen Davidoff, CEO, will provide a company progress update and outline planned activities for 2022. A pre-recorded presentation will be available via a provided link. Dr. Davidoff expressed enthusiasm about the opportunity to engage with global investors and pharmaceutical partners during this busy week of meetings associated with the JP Morgan virtual conference.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced the results of its 2021 Annual Meeting of Shareholders, where approximately 38% of shares were voted. All resolutions passed almost unanimously, including the election of six directors and the re-appointment of Smythe LLP as auditors. The company also approved a 10% rolling stock option plan. Following Raymond Pratt's appointment, 30,000 stock options were granted at $2.54 CAD, along with 56,495 options to independent directors. XORTX is developing therapies for progressive kidney diseases, including XRx-008 for ADPKD and XRx-101 for COVID-19-related kidney injury.
XORTX Therapeutics announced the filing of a provisional patent related to polycystic kidney disease (PKD), focusing on a new mechanism of injury tied to aberrant purine metabolism. This patent covers methods for diagnosing and treating PKD by addressing xanthine oxidase expression and uric acid levels. CEO Dr. Allen Davidoff highlighted the importance of these findings, which aim to expand the company's patent portfolio and enhance product development opportunities. The lead program, XRx-008, targets progressing kidney disease due to autosomal dominant PKD.
XORTX Therapeutics has announced the publication of a peer-reviewed study in the American Journal of Nephrology regarding hyperuricemia's implications in COVID-19 patients. The study, conducted with the Icahn School of Medicine, involved 834 hospitalized patients, revealing that 60% experienced acute kidney injury (AKI) and 31.7% died. Elevated serum uric acid was identified as a significant risk factor for AKI and mortality. XORTX's CEO emphasized the need for uric acid measurement in COVID-19 patients and the potential for uric acid-lowering treatments to improve outcomes.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced that A.G.P./Alliance Global Partners has initiated research coverage on the company. This marks a significant milestone for XORTX, which is developing innovative therapies for progressive kidney disease, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for COVID-19. The coverage report by James Molloy, a senior biotechnology analyst, emphasizes XORTX’s commitment to addressing critical health concerns. It can be accessed online or via direct contact with A.G.P.
XORTX Therapeutics has appointed Altasciences as the contract research organization for its planned bridging pharmacokinetic study, XRX-OXY-101, aimed at advancing therapies for autosomal dominant polycystic kidney disease (ADPKD) and acute kidney injury related to Coronavirus infections. This study will assess the bioavailability of oxypurinol following promising results in animal models. CEO Dr. Allen Davidoff emphasized that this marks the beginning of multiple clinical trials designed to enhance treatments for kidney diseases.
XORTX Therapeutics Inc. (TSXV: XRTX | NASDAQ: XRTX) has announced its annual and special meeting of shareholders scheduled for December 20, 2021. Shareholders will vote on key matters, including the election of directors and re-appointment of auditors. The company will feature a new board member, Dr. Raymond Pratt, who brings extensive experience in nephrology and drug development. Due to COVID-19 restrictions, the meeting will be held via conference call, and shareholders are encouraged to vote by proxy. XORTX is advancing therapies for kidney diseases and COVID-19.
Argus Research has begun coverage on XORTX Therapeutics (Nasdaq: XRTX), focused on innovative therapies for progressive kidney diseases. XORTX aims to advance its two leading candidates into Phase 3 trials in 2022, with a significant financing round completed in October 2021, raising approximately $13.5 million. The company anticipates additional funding from warrant exercises and has a fair value estimate of $13 per share, substantially higher than the current trading price of around $3. With a potent pipeline targeting conditions like autosomal-dominant polycystic kidney disease, XORTX shows strong market potential.
XORTX Therapeutics Inc. has completed a public offering, issuing an additional 355,000 common shares at US$4.129 each, raising approximately US$1.47 million. This follows the earlier announcement of total gross proceeds of about US$13.47 million from 3,261,000 shares and 3,341,900 warrants sold. Dr. Allen Davidoff, CEO, noted this investment reflects strong investor interest amid the company's NASDAQ uplisting. The offering is registered with the SEC, and further details can be accessed via the SEC’s website.
XORTX Therapeutics Inc. (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical company focused on kidney disease therapies, announced the de-listing of its common shares from the Canadian Securities Exchange (CSE) effective today. Trading will resume on the TSX Venture Exchange (TSXV) tomorrow without any need for shareholders to exchange share certificates. The company is advancing two clinical products: XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for acute kidney injury related to COVID-19. The CUSIP will remain unchanged for the common shares.
FAQ
What is the current stock price of Xortx Therapeutics (XRTX)?
What is the market cap of Xortx Therapeutics (XRTX)?
